Evidence map›Paper›PMID 38750208›Full record

ArticleNature reviews. Drug discovery2024

Tackling the challenges of new approach methods for predicting drug effects from model systems.

Paul D Pang, Syed Mukhtar Ahmed, Masataka Nishiga, Norman L Stockbridge, Joseph C Wu

Abstract readNews
In one paragraph

Article in Nature reviews. Drug discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Cardiac fibrosis: from mechanisms and models to medicines.Trends in pharmacological sciences · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paul D Pang
Syed Mukhtar Ahmed
Masataka Nishiga
Norman L Stockbridge
Joseph C Wu

Funding

Human iPSCs for Elucidating Intercellular Crosstalk Signaling in Dilated CardiomyopathyR01HL141371 · NHLBI · STANFORD UNIVERSITY · PI WONG, WING H., WU, JOSEPH C. · 2018 to 2025
$6.2M
Ethnically Diverse iPSC-Cardiomyocyte Panel for Pharmacogenomics and Drug Safety TestingR44HL170756 · NHLBI · GREENSTONE BIOSCIENCES, INC. · PI AHMED, SYED MUKHTAR · 2023 to 2024
$2.7M
Elucidating ECM Signaling in Cardiac Organoids with Machine Learning and Single-cell MultiomicsR01HL163680 · NHLBI · STANFORD UNIVERSITY · PI RAJADAS, JAYAKUMAR, WONG, WING H. · 2022 to 2025
$2.5M
AI/ML and iPSC-Derived Organoids for Myotonic Dystrophy Drug DiscoveryR21TR004938 · NCATS · GREENSTONE BIOSCIENCES, INC. · PI PANG, PAUL · 2024 to 2025
$303k
NCATS NIH HHS R21 TR004938NHLBI NIH HHS R01 HL141371NHLBI NIH HHS R01 HL163680NHLBI NIH HHS R44 HL170756
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Models, BiologicalDrug DiscoveryHumans

Identifiers

PMID38750208
PMCPMC11482555

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.